High Growth Tech Stocks In South Korea To Watch This September 2024

Over the last 7 days, the South Korean market has risen 2.2%, although it has been flat overall in the past year, with earnings expected to grow by 29% per annum over the next few years. In this context, identifying high-growth tech stocks that can capitalize on future earnings potential is crucial for investors looking to navigate these market conditions.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	33.61%	52.05%	★★★★★★
IMLtd	21.80%	111.43%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
NEXON Games	29.64%	66.98%	★★★★★★
Park Systems	23.64%	35.66%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
Daejoo Electronic Materials	42.24%	48.74%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★

Click here to see the full list of 42 stocks from our KRX High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Park Systems (KOSDAQ:A140860)

Simply Wall St Growth Rating: ★★★★★★

Overview: Park Systems Corp. develops, manufactures, and sells atomic force microscopy (AFM) systems worldwide with a market cap of ₩1.23 billion.

Operations: The company generates revenue primarily through the sale of atomic force microscopy (AFM) systems, with its Scientific & Technical Instruments segment contributing ₩148.23 billion. Gross profit margin stands at 51.2%.

Park Systems, renowned for its cutting-edge atomic force microscopy (AFM) technology, recently unveiled the Park FX200, designed for 200 mm samples. This innovation enhances measurement accuracy and efficiency with features like automatic probe recognition and advanced mechanical structure. The company’s earnings are projected to grow at an impressive 35.7% annually, outpacing the South Korean market's average of 29.1%. With R&D expenses contributing significantly to advancements—highlighted by a recent product launch—their revenue is forecasted to increase by 23.6% per year, surpassing industry expectations.

• Delve into the full analysis health report here for a deeper understanding of Park Systems.

• Learn about Park Systems' historical performance.

Intellian Technologies (KOSDAQ:A189300)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Intellian Technologies, Inc. is a South Korean company that specializes in providing satellite antennas and terminals both domestically and internationally, with a market cap of ₩518.23 billion.

Operations: Intellian Technologies generates revenue primarily through the sale of telecommunication equipment, amounting to ₩271.45 billion. The company focuses on satellite antennas and terminals for both domestic and international markets.

Intellian Technologies, a leader in satellite communication systems, is set to experience significant growth with revenue forecasted to rise by 33.4% annually, outpacing the South Korean market's 10.3%. The company has invested heavily in R&D, allocating KRW 14.2 billion last year to drive innovation and maintain its competitive edge. Despite being currently unprofitable, earnings are expected to grow by an impressive 90.37% per year over the next three years. Recent buybacks totaling KRW 4.99 billion for 89,000 shares indicate strong confidence in future performance and shareholder value enhancement.

• Unlock comprehensive insights into our analysis of Intellian Technologies stock in this health report.

• Explore historical data to track Intellian Technologies' performance over time in our Past section.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars with a market cap of ₩16.97 billion.

Operations: ALTEOGEN Inc. focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company generates revenue primarily from its biotechnology segment, amounting to ₩90.79 million.

ALTEOGEN is making strides in the biotech sector with its recent MFDS approval for Tergase®, a recombinant hyaluronidase boasting over 99% purity. This product, developed using Hybrozyme™ Technology, addresses multiple medical needs from dermal filler removal to pain management. The company's R&D expenses are significant, contributing KRW 14 billion last year to drive innovation. Revenue is expected to grow at an impressive 64.2% annually, outpacing the South Korean market's average of 10.3%.

• Click to explore a detailed breakdown of our findings in ALTEOGEN's health report.

• Review our historical performance report to gain insights into ALTEOGEN's's past performance.

Make It Happen

• Unlock our comprehensive list of 42 KRX High Growth Tech and AI Stocks by clicking here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com